JPRN-jRCT2021210079招募中1 期
A Phase 1/2 Study of Necitumumab plus Osimertinib for Advanced Non-small Cell Lung Cancer with EGFR-mutation - NEO-FORCE study
Maemondo Makoto0 个研究点目标入组 92 人开始时间: 2022年3月31日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 92
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1)A histologically or cytologically confirmed diagnosis of non-small-cell lung cancer
- •(2) Have clinical stage IIIB, IIIC, IVA, IVB that cannot be treated with radical radiotherapy and surgery or postoperative recurrent cases
- •*Practice for Lung Cancer (January 2017 [8th edition]). Japanese Lung Cancer Society/Edition
- •(3)An observed EGFR (Exon 19 deletion or Exon 21 L858R mutation) (However, mergers with uncommon mutations can be registered)
- •(4)With measurable lesions based on RECIST Ver 1.1. (Not required for Phase I)
- •(5)With no history of chemotherapy treatment for non-small-cell lung cancer (Preoperative and postoperative adjuvant chemotherapy, excluding EGFR inhibitors, is acceptable if 6 months have passed since the last dose. Pleurodesis is acceptable.)
- •(6)Aged >=20, at the time of consent
- •(7)ECOG PS 0-1
- •(8)Main organ functions must meet the following criteria within 14 days prior to enrollment. If there are multiple test results within this period, then the most recent test prior to enrollment will be adopted.
- •For measurement, should not do transfuse or administer hematopoietic factor preparations within 14 days before the test.
- •1)neutrophil >=1,500/mm3
- •2)hemoglobin >=9.0g/dL
- •3)platelet >=100,000/mm3
- •4)AST <=100 IU/L (with lung metastasis, <=200 IU/L)
- •5)ALT <=100 IU/L (with lung metastasis, <=200 IU/L)
- •6)bilirubin <=1.5mg/dL (with lung metastasis, <=3.0mg/dL)
- •7)serum creatinine >=45 ml/min
- •8) SpO2 >=93%
- •(9)Written informed consent
排除标准
- •(1)Have active interstitial lung disease, or a history of drug-induced pneumonitis, radiation pneumonitis needing steroid treatment.
- •(2)No major surgery within 4 weeks before registration
- •(3)With brain metastasis or spinal cord compression that is not clinically stable. However, patients who do not require steroids and are neurologically stable for at least 2 weeks after completion of definitive and steroid therapy will not be excluded.
- •(4)Currently have serious complications including uncontrolled heart, lung, liver, and renal disease.
- •(5)Receiving steroids more than 4 weeks (10mg prednisolone equivalent or more) or immunosuppressants
- •(6) Cases that meet any of the following heart-related criteria
- •1)With resting correction QT interval (QTcF) greater than 470 msec
- •2)Have severe coronary disease, uncontrollable congestive heart failure (NYHA III or IV), or uncontrollable arrhythmia, uncontrollable hypertension despite antihypertensive treatment (Systolic pressure =>150 mmHg or diastolic pressure =>90 mmHg)
- •(7)With or a history of thromboembolic disease
- •(8)With active hepatitis B and C (HBsAg positive, HBs antibody positive, HBc antibody positive, HBV DNA should be measured. HBV DNA positive is excluded.)
- •(9)Women who are currently pregnant or breastfeeding. If breastfeeding is discontinued before participation in the study, lactation should be discontinued during the study period and at least 30 days after the end of drugs used in the Clinical Trial administration.
- •(10)With intractable nausea and vomiting, chronic gastrointestinal disease, dysphagia of the preparation, total gastrectomy and serious bowel resection that prevents adequate absorption of osimertinib
- •(11)Have pleural effusion, ascites or pericardial effusion that require drainage
- •(However, cases in which pleural effusion is controlled for 2 weeks before enrollment by drainage or pleurodesis are not excluded.)
- •(12)Have contraindication to osimertinib and necitumumab.
- •(13)Have complications with double cancers that have a disease-free period of less than 5 years (enrollment is permitted if intraepithelial carcinoma and intramucosal carcinoma lesions have been judged as cured from localized treatment regardless of the disease-free period).
- •(14)Impossible to take drugs orally
- •(15)With a history of hypersensitivity to osimertinib (or drugs of the same chemical structure or class as osimertinib) or necitumumab or vehicle for these drugs.
- •(16)Patients whose participation in the trial is judged to be inappropriate by the doctor
研究者
相似试验
进行中（未招募）
2 期
A Phase 2 Study of Osimertinib in combination with Platinum-pemetrexed in patients with EGFR-mutated Advanced non-small cell Lung cancer.on-squamous non-small cell lung cancerJPRN-jRCTs031180226Kobayashi Kunihiko66
进行中（未招募）
2 期
Phase II study of necitumumab and pembrolizumab in patients with PD-L1 high-expressing non-small-cell lung cancerPD-L1 high-expressing non-small-cell lung cancernon-small cell lung cancerJPRN-jRCT2031200248Horiike Atsushi50
招募中
1 期
A Phase I/II Study of necitumumab + carboplatin + nab-paclitaxel + pembrolizumab for previously untreated advanced squamous non-small cell lung cancer studysquamous non-small cell lung cancer(SqCLC)JPRN-jRCT2031210387Seike Masahiro60
进行中（未招募）
1 期
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase InhibitorMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8NCT02496663National Cancer Institute (NCI)138
已完成
不适用
A Phase Ib study of osimertinib with ramucirumab in EGFR mutated lung adenocarcinoma patients. (LY3009806-IIT-01)JPRN-UMIN000030142Wakayama Medical University6